This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (633)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

D. R. LUCAS, M.D.; J. P. NEWHOUSE, B.Sc.

AMA Arch Ophthalmol. 1957;58(2):193-201.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

L-Glutamic acid and its sodium salt have been widely used in the oral treatment of petit mal and mental deficiency (e. g., Zimmerman, Burgemeister, and Putnam, 1949; Milliken and Standen, 1951). Single doses of 20-30 gm. have also been administered intravenously without permanent illeffects (Sapirstein, 1943; Elman, 1946; Mayer-Gross and Walker, 1949; Weil-Malherbe, 1949).

During an investigation of the influence of various substances of biochemical importance upon the progress in the mouse of an hereditary retinal dystrophy it was observed that the parenteral administration of sodium L-glutamate damaged the inner layers of the retina, which are not themselves involved in the genetic lesion. Since this lesion could also be produced in normal mice, a limited study was made of its histological development and the conditions necessary for its appearance in mouselings and adults of the Strong A2 (Glaxo) strain. Among substances related chemically or physiologically to glutamate, which were also . . . [Full Text PDF of this Article]

Author Affiliations
London, England

Wernher Group for Research in Ophthalmological Genetics (Medical Research Council), Royal College of Surgeons of England.

Footnotes
Received for publication Feb. 1, 1957.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?